Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 7, 1999, Pages 1757-1760

  Weltermann, Ansgar ^a   Wolzt, Michael ^b   Petersmann, Kai ^a   Czerni, Christine ^a   Graselli, Ursula ^b   Lechner, Klaus ^a   Kyrle, Paul A ^a,c  

^a Division of Hematology   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Coagulation activation; Prothrombin fragment 1.2; Recombinant hirudin; Vascular endothelial growth factor; thromboglobulin

Indexed keywords

LEPIRUDIN; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD CLOTTING; DISEASE MARKER; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN SECRETION; THROMBOCYTE ACTIVATION; THROMBUS;

EID: 0033000420     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.7.1757     Document Type: Article

References (30)

1. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS. 1997;79:1-8.
2. Ferrara N. Vascular endothelial growth factor. Eur J Cancer. 1996;32A: 2413-2422.
3. Connolly DT. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem. 1991;47:219-223.
4. Ferrara N, Heinsohn H, Walder CE, Bunting S, Thomas GR. The regulation of blood vessel growth by vascular endothelial growth factor. Ann N Y Acad Sci. 1995;752:246-256.
5. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108:2369-2379.
6. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336-3343.
7. Gruber BL, Marchese MJ, Kew R. Angiogenic factors stimulate mast-cell migration. Blood. 1995;86:2488-2493.
8. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991;5:1806-1814.
9. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol. 1995;107:233-235.
10. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993;4:1317-1326.
11. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84:1470-1478.
12. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
13. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
14. Möhle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94:663-668.
15. Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998;77:956-964.
16. Thorngren M, Shafi S, Born GV. Thromboxane A2 in skin-bleeding-time blood and in clotted venous blood before and after administration of acetylsalicylic acid. Lancet. 1983;1:1075-1078.
17. Kyrle PA, Westwick J, Scully MF, Kakkar VV, Lewis GP. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man-effect of low-dose aspirin. Thromb Haemost. 1987;57:62-66.
18. Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood. 1988;71:629-635.
19. Gerrard JM, Taback S, Singhroy S, et al. In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 alpha in humans in response to a standardized vascular injury and the influence of aspirin. Circulation. 1989;79:29-38. Comment.
20. Eichinger S, Wolzt M, Schneider B, et al. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo: comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin). Arterioscler Thromb Vasc Biol. 1995;15: 886-892.
21. Kyrle PA, Brockmeier J, Weltermann A, et al. Inhibition rather than enhancement of hemostatic system activation during initiation of oral anticoagulant treatment. Thromb Haemost. 1997;77:685-689.
22. Mielke CH, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood. 1969;34:204-215.
23. Shweiki D, Itin A, Softer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
24. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848.
25. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 1996;56:4032-4039.
26. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326: 975-982. Comment.
27. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-445.
28. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer: "Petites Cellules" Group. Cancer. 1994;74:38-45.
29. Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer using low-molecular-weight heparins. Haemostasis. 1997; 27(suppl 1):32-37.
30. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593-1596. Comment.